Open access
Open access
Powered by Google Translator Translator

Onco-hematology

ESC Position Statement: Diagnosis and treatment of cardiac amyloidosis

8 Apr, 2021 | 08:49h | UTC

Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases – European Heart Journal

 

Commentary on Twitter (thread – click for more)

 


Recent progress in the treatment of cancer in children

5 Apr, 2021 | 01:15h | UTC

Recent progress in the treatment of cancer in children – CA: A Cancer Journal for Clinicians

 


Cohort study: High thrombotic risk in cancer patients receiving immunotherapy

5 Apr, 2021 | 01:08h | UTC

High thrombotic risk in cancer patients receiving immunotherapy – Medical University of Vienna

Original study: Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy – Blood

 


Preliminary study finds a low-calorie diet and mild exercise may improve survival for young people with leukemia

2 Apr, 2021 | 09:12h | UTC

Caloric and nutrient restriction to augment chemotherapy efficacy for acute lymphoblastic leukemia: the IDEAL trial – Blood Advances

Commentary: Low-calorie diet and mild exercise improve survival for young people with leukemia – University of California, Los Angeles (UCLA)

 


RCT: Effect of Blinatumomab vs. Chemotherapy in children with high-risk first-relapse B-Cell Acute Lymphoblastic Leukemia

3 Mar, 2021 | 08:19h | UTC

Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial – JAMA (free for a limited period)

Related study: Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Blinatumomab for Treatment of Children With High-risk Relapsed B-Cell Acute Lymphoblastic Leukemia – JAMA (free for a limited period)

 


CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma

26 Feb, 2021 | 08:31h | UTC

CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma – Dana-Farber Cancer Institute

Original study: Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma – New England Journal of Medicine

 


Integrated palliative and oncology care for patients receiving treatment for acute myeloid leukemia

26 Feb, 2021 | 08:25h | UTC

Integrated Palliative and Oncology Care for Patients Receiving Treatment for Acute Myeloid Leukemia – The ASCO Post

Original article: Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

 


Randomized trial: Oral Azacitidine maintenance therapy for acute myeloid leukemia in first remission

26 Feb, 2021 | 08:23h | UTC

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Maintenance Oral Azacitidine for Patients With AML in First Remission: QUAZAR AML-001 Trial – The ASCO Post

 


Defining the optimal total number of chemotherapy courses in younger patients with Acute Myeloid Leukemia: A comparison of 3 vs. 4 courses

19 Feb, 2021 | 02:06h | UTC

Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Optimal Number of Treatment Courses Explored in Younger Patients with AML – CancerNetwork

 

Commentary on Twitter

 


Short review: Acute CV complications of hematopoietic stem cell transplantation

18 Feb, 2021 | 02:40h | UTC

Acute CV Complications of Hematopoietic Stem Cell Transplantation – American College of Cardiology

 


ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer

15 Feb, 2021 | 00:49h | UTC

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer – Blood Advances

Commentary: ASH 2021 Guidelines for Prevention and Treatment of Venous Thromboembolism in Patients With Cancer – The ASCO Post

 


RCT: Total Body Irradiation vs. Chemotherapy Conditioning in Childhood ALL

9 Feb, 2021 | 00:39h | UTC

Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study – Journal of Clinical Oncology

Commentary: TBI Beats Chemoconditioning for ALL Transplants in Children – Medscape (free registration required)

 

Commentary on Twitter

 


Patients with lymphoma receiving B-Cell–depleting therapies may be at greater risk for persistent COVID-19 infection

9 Feb, 2021 | 01:14h | UTC

Patients With Lymphoma Receiving B-Cell–Depleting Therapies May Be at Greater Risk for Persistent COVID-19 Infection – The ASCO Post

Related: Patients on Active Chemotherapy May Not Be at Increased Risk for COVID-19 Infection – The ASCO Post

See also: Anti-CD20 Drugs Tied to Severe COVID in Cancer Patients — Plus: Active chemo treatment may not be a COVID risk factor – MedPage Today (free registration required)

 


Clinical Cancer Advances 2021: ASCO’s Report on Progress Against Cancer

7 Feb, 2021 | 20:45h | UTC

Clinical Cancer Advances 2021: ASCO’s Report on Progress Against Cancer – Journal of Clinical Oncology

Commentary: ASCO Names Molecular Profiling in GI Cancers as Advance of the Year – OncLive

 


Preliminary study shows sitagliptin may prevent acute Graft-versus-Host Disease

26 Jan, 2021 | 00:35h | UTC

Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Sitagliptin promising addition for preventing acute GVHD – HealthDay

 


Stay Updated in Your Specialty

No spam, just news.